All Articles

Molecular Testing Is Advised in Patients with Stage I-III Non–Small-Cell Lung Cancer

A recent review of the various approaches to developing new therapeutic drugs to treat KRAS-harboring tumors also discusses emerging drugs.

Aspirin Use Improves Survival in Patients with Inoperable Non–Small-Cell Lung Cancer

Molecular testing of early-stage non–small-cell lung cancer is recommended after clinical trial results demonstrate osimertinib is effective for patients with EGFR-harboring tumors.

Neurologic Adverse Events Are a Rare but Concerning Side Effect of Immune Checkpoint Inhibitor Use

A retrospective cohort study demonstrates patients with inoperable non–small-cell lung cancer receiving aspirin have improved overall survival compared with patients not receiving aspirin.

A Subanalysis of the Phase 3 MONARCH 3 Study of Abemaciclib as Initial Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer

A recent review of case reports of patients with non–small-cell lung cancer receiving immune checkpoint therapy finds neurologic adverse events are a rare but concerning side effect.

Effectiveness of Alpelisib plus Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR-Positive, HER2-Negative, PIK3CA Mutation–Positive Breast Cancer

Abemaciclib plus nonsteroidal aromatase inhibitors were shown to be a successful initial treatment in a Japanese subpopulation, with a tolerable safety profile, consistent with findings in the whole population in treating patients with HR-positive, HER2-negative advanced breast cancer.

Updates on Endocrine Therapy for Metastatic Breast Cancer

The therapeutic advantage of alpelisib over fulvestrant in the treatment of patients with HR-positive, HER2-negative breast cancer and other malignancies is further enhanced by a matched/weighted analysis comparing BYLieve with the real-world scenario.

Patient-Reported Outcomes from a Phase 3 Trial in Premenopausal Patients with ER-Positive, HER2-Negative, Lymph Node–Positive Breast Cancer

Endocrine therapy used in combination with CDK4/6 inhibitors, in particular, have transformed the metastatic breast cancer landscape, promisingly improving progression-free survival and overall survival among patients with HR-positive, HER2-negative metastatic breast cancer.

Checkpoint Inhibitor Therapy for Metastatic Triple-Negative Breast Cancer

Neoadjuvant chemotherapy is becoming more popular for patients with locally advanced breast cancer. Downstaging may result in a smaller surgical extent or a higher breast conservation rate, and a better cosmetic outcome. Chemotherapy, on the other hand, has both short- and long-term complications.